At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 45 enrolled
Drug / intervention
Ketamine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ketamine Efficacy for Acute Severe Bronchospasm in Mechanically Ventilated-critically Ill Patients: a Randomized Controlled Trial
In Brief
A Phase 3 clinical trial evaluating Ketamine and Fentanyl for Critical Illness and 2 related conditions. Completed, enrolled 45 participants across 1 site.
Detailed Summary
Despite few scientific evidence that could support the use of ketamine in adult patients undergoing acute bronchospasm requiring mechanical ventilation (MV), ketamine is largely employed in this setting. The aim of this study is therefore assess more definitively the real benefit of using ketamine in patients with severe bronchospasm, requiring ICU stay and need for MV in order to establish or refute the use of this drug as "standard therapy" in these cases.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCritical Illness, Asthma, Bronchospasm
CountriesBrazil
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedDec 2016
Primary CompletionJun 2017
Study CompletionJan 2018
TodayJul 2026
First PostedDec 22, 2016
Enrollment StartJun 4, 2015
Primary CompletionJun 16, 2017
Study CompletionJan 29, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.5 years ago
Interventions
Ketaminedrug
Active treatment
Fentanyldrug